Controlled Release, Intestinal Transport, and Oral Bioavailablity of Paclitaxel Can be Considerably Increased Using Suitably Tailored Pegylated Poly(Anhydride) Nanoparticles
- 1 September 2015
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 104 (9) , 2877-2886
Abstract
No abstract availableKeywords
Funding Information
- Fiss Grant, Instituto Salud Carlos III, Spain (FI08/00527)
- Mnisterio de Ciencia y TecnologÃa, Spain (SAF2008-02538)
This publication has 37 references indexed in Scilit:
- Oral Cancer Chemotherapy: The Critical Interplay Between Patient Education and Patient SafetyCurrent Oncology Reports, 2010
- Tubulin-Interactive Natural Products as Anticancer AgentsJournal of Natural Products, 2009
- Enhanced Oral Paclitaxel Bioavailability After Administration of Paclitaxel-Loaded Lipid NanocapsulesPharmaceutical Research, 2006
- Oral chemotherapy: potential benefits and limitationsClinical and Translational Oncology, 2004
- Oral cancer treatment: developments in chemotherapy and beyondBritish Journal of Cancer, 2002
- Answering Patients' Needs: Oral Alternatives to Intravenous TherapyThe Oncologist, 2001
- Semisynthesis of D-Ring Modified Taxoids: Novel Thia Derivatives of DocetaxelThe Journal of Organic Chemistry, 2001
- Neutral and Basic Taxoid Contents in the Needles of Taxus SpeciesPlanta Medica, 2000
- Paclitaxel (Taxol)New England Journal of Medicine, 1995
- First total synthesis of taxol. 2. Completion of the C and D ringsJournal of the American Chemical Society, 1994